Inhibitors of Src and Lck protein kinases

A compound of formula I:

• 348
• or a pharmaceutically acceptable derivative thereof, wherein:
• A-B is N—O or O—N;
• R1 is selected from halogen, NO2, TYR, or TCN;
• each T is independently selected from an optionally substituted C1-C6 alkylidene chain, wherein:
• one methylene unit of T is optionally replaced by O, NR, NRC(O), C(O)NR, NRC(O)NR, C(O), C(O)CH2C(O), C(O)C(O), C(O)0, OC(O), NRSO2, S, SO, SO2NR, or SO2;
• y is zero or one;
• each R is independently selected from hydrogen or an optionally substituted C1-C6 aliphatic group, or:
• two R on the same nitrogen are taken together with the nitrogen to form a 3-7 membered saturated, partially unsaturated, or fully unsaturated ring having 1-2 heteroatoms, in addition to the nitrogen bound thereto, independently selected from nitrogen, oxygen, or sulfur;
• R2 is R or Ar1;
• G is selected from XmR or XmAr1;
• each m is independently selected from zero or one;
• X is selected from O, S, SO, SO2, NH, C(O), C(O)NH, NHC(O), NHC(O)NH, SO2NH, NHSO2, or NHSO2NH;
• each Ar1 is independently selected from an optionally substituted ring selected from a 5-7 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• R3 is selected from ZQnR5 or ZQnR7, wherein ZQnR7 is not hydrogen;
• Q is an optionally substituted C1-C6 alkylidene chain wherein:
• one or two non-adjacent methylene units of Q are optionally and independently replaced by O, NR, NRC(O), C(O)NR, C(O), S, SO, SO2, or SO2NR;
• provided that said optionally replaced methylene unit of Q is a methylene unit non-adjacent to R7;
• each n is independently selected from zero or one;
• Z is selected from a valence bond, O, S, SO, SO2, NH, C(O), C(O)NH, NHC(O), SO2NH, or NHSO2;
• R4 is selected from R, halogen, NO2, CN, OR, SR, N(R)2, NRC(O)R, NRC(O)N(R)2, NRCO2R, C(O)R, CO2R, OC(O)R, C(O)N(R)2, OC(O)N(R)2, SOR, SO2R, SO2N(R)2, NRSO2R, NRSO2N(R)2, C(O)C(O)R, or C(O)CH2C(O)R, or:
• two R4 on adjacent positions of the phenyl ring are taken together to form a saturated, partially unsaturated, or fully unsaturated 5-7 membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• R5 is Ar1, wherein R5 is optionally substituted with up to three R6;
• each R6 is independently selected from R, halogen, NO2, CN, OR, SR, N(R)2, NRC(O)R, NRC(O)N(R)2, NRCO2R, C(O)R, CO2R, C(O)N(R)2, OC(O)N(R)2, SOR, SO2R, SO2N(R)2, NRSO2R, NRSO2N(R)2, C(O)C(O)R, or C(O)CH2C(O)R, or:
• two R6 on adjacent positions of R5 are taken together to form a saturated, partially unsaturated, or fully unsaturated 5-7 membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• and R7 is selected from R, halogen, NO2, CN, OR, SR, N(R)2, NRC(O)R, NRC(O)N(R)2, NRCO2R, C(O)R, CO2R, OC(O)R, C(O)N(R)2, OC(O)N(R)2, SOR, SO2R, SO2N(R)2, NRSO2R, NRSO2N(R)2, C(O)C(O)R, or C(O)CH2C(O)R;
• provided that:
• (a) when R3 is ZQR7, R1 is other than hydrogen, and
• (b) when R1 is hydrogen, R5 is other than phenyl.